SAN FRANCISCO, Feb. 13, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will participate in the Bank of America Merrill Lynch Animal Health Summit on February 26, 2018 in New York City.
Richard Chin, M.D., President and Chief Executive Officer, will participate in a panel discussion entitled, "Innovation in Companion Animal Therapeutics." The event will also feature one-on-one meetings at which investors will have the opportunity to meet with Dr. Chin to discuss KindredBio's key therapeutic programs in development and upcoming milestones.
About Kindred Biosciences
Kindred Biosciences is a pre-commercialization stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.
For more information or to download the corporate presentation, visit www.KindredBio.com/LearnMore. Stay connected with KindredBio on Facebook at www.Facebook.com/KindredBio.
Contact
Russell Radefeld
KindredBio
russell.radefeld@kindredbio.com
(650) 701-7904
View original content with multimedia:http://www.prnewswire.com/news-releases/kindred-biosciences-to-participate-in-the-bank-of-america-merrill-lynch-animal-health-summit-300597560.html
SOURCE Kindred Biosciences, Inc.
